Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma

• Published in: Pediatric Blood & Cancer Vol. 51; no. 5; pp. 675 - 678
• Main Authors: Kadota, Richard P., Mahoney, Donald H., Doyle, John, Duerst, Reggie, Friedman, Henry, Holmes, Emi, Kun, Larry, Zhou, Tianni, Pollack, Ian F.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2008
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; autograft; Central Nervous System Neoplasms - drug therapy; Central Nervous System Neoplasms - mortality; chemotherapy; Child; Child, Preschool; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; germinoma; Germinoma - drug therapy; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; medulloblastoma; Medulloblastoma - drug therapy; Medulloblastoma - mortality; Melphalan - administration & dosage; Melphalan - adverse effects; Neoplasm Recurrence, Local - drug therapy; Transplantation, Autologous
• ISSN: 1545-5009; 1545-5017; 1096-911X
• DOI: 10.1002/pbc.21655

Purpose To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. Patients and Methods Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2. Results Twenty‐nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow‐up of 7.5 years (range = 2.8–10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. Conclusion Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long‐term survivors. Pediatr Blood Cancer 2008;51:675–678. © 2008 Wiley‐Liss, Inc.